<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471210</url>
  </required_header>
  <id_info>
    <org_study_id>CA186-011</org_study_id>
    <secondary_id>2012-000170-28</secondary_id>
    <nct_id>NCT01471210</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety, tolerability, pharmacokinetics and
      immunoregulatory activity of urelumab (BMS-663513) in cancer subjects with advanced and/or
      metastatic tumors and relapsed/refractory B-Cell Non-Hodgkin's Lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests</measure>
    <time_frame>Every 3 weeks from Baseline (Day 1) for up to 2 years</time_frame>
    <description>The incidence of adverse events will be tabulated and reviewed for potential significance and clinical Importance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity and maximum tolerated dose of Urelumab (BMS-663513) as determined by the incidence of dose-limiting toxicities</measure>
    <time_frame>Every 3 weeks from Baseline (Day 1) for up to 9 weeks of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentrations (Cmax) of Urelumab (BMS-663513)</measure>
    <time_frame>Cycle 1 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum observed serum concentrations (Cmin) of Urelumab (BMS-663513)</measure>
    <time_frame>Cycle 2 Day 1, Cycle 3 Day 1, every 12 weeks thereafter up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) of Urelumab (BMS-663513)</measure>
    <time_frame>Cycle 1 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in 1 dosing interval [AUC(TAU)] of Urelumab (BMS-663513)</measure>
    <time_frame>Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life (T-HALF) of Urelumab (BMS-663513)</measure>
    <time_frame>Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CLT) of Urelumab (BMS-663513)</measure>
    <time_frame>Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady-state (Vss) of Urelumab (BMS-663513)</measure>
    <time_frame>Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Anti-human Antibodies</measure>
    <time_frame>Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years</time_frame>
    <description>Immunogenicity of Urelumab (BMS-663513), as determined by blood sample measurements of human antihuman antibodies (HAHA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response and progression as determined by proportion of patients with best overall response (BOR), progression-free survival (PFS), objective response rate (ORR), time to response, and duration of response</measure>
    <time_frame>9 weeks from Baseline (Day 1) and every 9 weeks until disease progression, death or last tumor assessment (Approximately up to 2 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Part 1 : Urelumab (BMS-663513) Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Urelumab (BMS-663513) solution administered intravenously on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 : Urelumab (BMS-663513) Cohort Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Urelumab (BMS-663513) solution administered intravenously on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3:Urelumab (BMS-663513) Tumor-specific Cohort Expansions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrollment of subjects of three specific tumor types [(colorectal cancer (CRC), head and neck squamous cell carcinoma (SCCHN), and B-Cell non-Hodgkin's lymphoma (B-NHL)] who will be treated at the Maximum Tolerated Dose (MTD) (or highest dose tested)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 4:Urelumab (BMS-663513) Cohort Expansion in B-NHL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A and Arm B: Urelumab (BMS-663513) liquid administered intravenously on specified days exploring q3w and q6w dosing regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urelumab (BMS-663513)</intervention_name>
    <arm_group_label>Part 1 : Urelumab (BMS-663513) Dose escalation</arm_group_label>
    <arm_group_label>Part 2 : Urelumab (BMS-663513) Cohort Expansion</arm_group_label>
    <arm_group_label>Part 3:Urelumab (BMS-663513) Tumor-specific Cohort Expansions</arm_group_label>
    <arm_group_label>Part 4:Urelumab (BMS-663513) Cohort Expansion in B-NHL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          1. Signed Written Informed Consent

               -  The signed informed consent form

          2. Target Population

               -  Subjects with advanced and/or metastatic solid tumors or B-NHL who are either
                  refractory to or have relapsed from standard therapies, or for whom a standard
                  therapy does not exist with measurable disease per Response Evaluation Criteria
                  in Solid Tumors (RECIST) 1.1 criteria

               -  Life expectancy of 12 weeks or greater

               -  Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 1

               -  Adequate organ and marrow function

               -  For certain subjects, willing and able to provide pre- and post-treatment fresh
                  tumor biopsies

          3. Age and Reproductive Status

               -  Women of childbearing potential (WOCBP) and men must be using an acceptable
                  method of contraception to avoid pregnancy throughout the study and for at least
                  4 weeks prior to initiation of dosing, and for at least 60 days after the last
                  dose of investigational product in such a manner that the risk of pregnancy is
                  minimized

               -  WOCBP must have a negative serum or urine pregnancy test [minimum sensitivity 25
                  UI/L or equivalent units of human chorionic gonadotrophin (HCG)] within 24 hours
                  prior to the start of investigational product

               -  Women must not be breastfeeding

        Exclusion Criteria:

          1. Target Disease Exceptions

               -  Subjects with known or suspected brain metastasis unless previously treated and
                  without evidence of progression

               -  Subjects with a history of prior malignancy active within the previous 2 years
                  except for locally curable cancers that have been apparently cured

               -  Subjects with hepatocellular carcinoma

          2. Medical History and Concurrent Diseases

               -  Any active autoimmune disease or documented history of autoimmune disease, or
                  history of syndrome that required systemic steroids or immunosuppressive
                  medications, except for subjects with vitiligo, psoriasis inactive within past 2
                  years, resolved childhood asthma/atopy, or thyroid disease controlled by
                  replacement therapy without the need for immunosuppression

               -  Known or suspected human immunodeficiency virus (HIV) or hepatitis A(acute), B or
                  C infection

               -  History of any hepatitis (e.g., alcohol or non-alcohol steatohepatitis (NASH),
                  drug-related, auto-immune)

               -  Evidence of active infection, requiring parenteral anti-bacterial, anti-viral or
                  anti-fungal therapy &lt; 7 days prior to administration of study medication

               -  History of clinically significant cardiac disease, including but not limited to a
                  history (personal or family) of congenital long QT syndrome

               -  Grade &gt; 1 QTc prolongation at baseline (&gt; 450 msec by Bazett formula) confirmed
                  by a repeat electrocardiogram (ECG)

               -  History of myocardial infarction or uncontrolled angina within 12 months prior to
                  administration of study drug

          3. Physical and Laboratory Test Findings

               -  WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy
                  for the entire study period and for up to 12 weeks after the last dose of
                  investigational product

               -  Women who are pregnant or breastfeeding

               -  Women with a positive pregnancy test on enrollment or prior to investigational
                  product administration

               -  Sexually active fertile men not using effective birth control if their partners
                  are WOCBP

               -  Positive blood screen for hepatitis A IgM, hepatitis C antibody, hepatitis B
                  surface antigen, or HIV-1, -2 antibody

          4. Allergies and Adverse Drug Reaction

               -  History of allergy to Urelumab (BMS-663513) or related compounds

               -  History of significant drug allergy (such as anaphylaxis or hepatotoxicity) to a
                  prior biologic therapy

          5. Prohibited Treatments and/or Therapies

               -  The systemic use of the following therapies are prohibited within 28 days of
                  first dose of study medication, or longer where indicated:

                    1. Use of anti-cancer treatment (including investigational drugs) within 28
                       days

                    2. Immunosuppressive medications or immunosuppressive doses of systemic
                       corticosteroids

                    3. Surgery (except minor surgeries,e.g., biopsies) or radiotherapy

                    4. Any non-oncology live viral vaccine therapies used for the prevention of
                       infectious diseases.

               -  Prior treatment with anti-programmed death 1 (anti-PD-1)/Programmed cell death 1
                  ligand 1 (PD-L1) or anti-CD137

               -  Any subject with the following reported drug-related adverse events on anti-
                  Cytotoxic T-Lymphocyte Antigen 4 (anti-CTLA4) will not be permitted on study:
                  hepatic, diarrhea/colitis or endocrine adverse events (AE)s Grade â‰¥ 2, any other
                  non-laboratory immune-related AE â‰¥ Grade 3. Subjects must have minimum 9 week
                  washout period between the last dose of anti-CTLA4 and the first dose Urelumab
                  (BMS-663513)

               -  Prior organ allograft or allogeneic bone marrow transplantation

          6. Other Exclusion Criteria

               -  Prisoners or subjects who are involuntarily incarcerated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division Of Hematology &amp; Oncology Ctr. For Health Sciences</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Med Ctr</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Of The University Of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Creteil Cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rouen</city>
        <zip>F-76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pamplona</city>
        <zip>31192</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2011</study_first_submitted>
  <study_first_submitted_qc>November 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2011</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

